Pressure BioSciences Inc. (NSDQ:PBIO) seated Alan Goldberg to its board of directors, the company announced today.
Goldberg, who first invested in the Pressure BioSciences in 2007, filled a seat that has been vacant since the South Easton, Mass.-based company’s shareholders voted to amend the its articles of incorporation and divide the board into three classes, according to the company.
"We are thrilled to have Alan join our Board, especially now, as we begin to focus on the commercialization of several … applications of our novel and powerful pressure cycling technology platform,” said Pressure BioSciences CEO R. Wayne Fritzsche in prepared remarks.
In late May, the company signed a research & development deal with the Armed Forces Institute of Pathology, the Dept. of Veterans Affairs and the American Registry of Pathology.
The company suffered a small decline in first-quarter revenues as overall sales for the three months ended March 31 were $291,000, down about $16,000 from the year-ago period. The net loss during the quarter was $911,000, or more than four times the $224,000 reported for the first quarter of 2009.
